Benralizumab

Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα) -directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma[1].

Product Specifications

CAS Number

[1044511-01-4]

Product Name Alternative

MEDI-563; BIW-8405; KHK4563

UNSPSC

12352203

Target

Apoptosis; Interleukin Related

Type

Inhibitory Antibodies

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/benralizumab.html

Purity

99.1

Solubility

H2O

Smiles

[Benralizumab]

Molecular Weight

(146.06 kDa)

References & Citations

[1]Menzies-Gow A, et al. Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial. ERJ Open Res. 2019 Sep 25;5 (3) . pii: 00009-2019.|[2]Kolbeck R, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010 Jun;125 (6) :1344-1353.e2.